INOVIQ Ltd (ASX:IIQ)

Australia · Delayed Price · Currency is AUD

0.1600

-0.0100 (-5.88%)

Oct 7, 2026, 2:25 PM AEST

Market Cap	22.52M -49.6%
Revenue (ttm)	2.21M +22.0%
Net Income	-7.51M
EPS	-0.06
Shares Out	140.78M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	261,803
Open	0.1650
Previous Close	0.1700
Day's Range	0.1550 - 0.1650
52-Week Range	0.1550 - 0.5650
Beta	1.48
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 17, 2026

About INOVIQ

INOVIQ Ltd develops and commercializes diagnostic and exosome‐based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an immunoaffinity magnetic bead-based isolation system for exosome isolation from plasma, serum, urine, saliva and cell-conditioned medium. It also offers non-invasive diagnostics using its proprietary exosome development technologies fo... [Read more]

Industry Diagnostics & Research

Sector Healthcare

Founded 2016

Employees 15

Stock Exchange Australian Securities Exchange

Ticker Symbol IIQ

Full Company Profile

Financial Performance

In fiscal year 2026, INOVIQ's revenue was 2.21 million, an increase of 21.98% compared to the previous year's 1.82 million. Losses were -7.51 million, 8.26% more than in 2025.

Financial Statements